Joseph T. Giacino, PhD is the Director of Rehabilitation Neuropsychology and Research Associate in the Department of Physical Medicine and Rehabilitation at Spaulding Rehabilitation Hospital in Boston, Massachusetts, Consulting Neuropsychologist in the Department of Psychiatry at Massachusetts General Hospital, Associate Professor in the Department of Physical Medicine and Rehabilitation at Harvard Medical School and Adjunct Professor at the MGH Institute of Health Professions. He directs the Spaulding Rehabilitation Hospital Neurorehabilitation Laboratory which focuses on the development and application of novel assessment and treatment methods for individuals with severe acquired brain injury (ABI) and disorders of consciousness (DoC). He served as co-chair of the Aspen Workgroup which established the diagnostic criteria for the minimally conscious state (MCS) and currently chairs the DoC Guideline Development Panel, co-sponsored by the American Academy of Neurology, American Congress of Rehabilitation Medicine and National Institute on Disability, Independent Living and Rehabilitation Research (NIDILRR). He currently directs the Spaulding-Harvard TBI Model System (NIDILRR), serves as Co-PI on the “Transforming Research and Clinical Knowledge in TBI (TRACK-TBI)” (NIH-NINDS) and “TBI Endpoint Development (TED)” (DoD) projects, both of which are validating clinical, imaging, genomic and outcome markers designed to enable more precise TBI diagnosis, prognosis and treatment. He is also Co-PI on an NINDS-funded Advanced Neural Prosthetics Research and Development grant investigating “Central Thalamic Stimulation for Traumatic Brain Injury” and PI on a TED seed grant that is developing an Evidence-Based Clinical Outcome Assessment Platform for evaluation of TBI clinical outcome assessment measures intended for use in FDA-approved drug and device trials. In his clinical role, Dr. Giacino directs the Spaulding Rehabilitation Network DoC Program and maintains a broad array of national and international collaborations aimed at improving care for patients with severe TBI.